Vitro Biopharma, Inc

About Us

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG; http://www.vitrobiopharma.com), owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitro also owns a pending international patent for generation of pluripotent stem cells. Vitro’s mission is “Harnessing the Power of Cells™” for the advancement of regenerative medicine to its full potential. Vitro operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado. Vitro manufactures and sells “Tools for Stem Cell and Drug Development™”, including human mesenchymal stem cells and derivatives, MSC-Gro™ optimized media for stem cell self-renewal and lineage-specific differentiation. Vitro recently formed a strategic alliance with HemoGenix®, Inc. to jointly manufacture and distribute LUMENESC™ and LumiSTEM™ quantitative assays for determination of stem cell quality, potency and response to toxic agents.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Vitro Biopharma Responds to Recent Market Activity

Tue, May 01, 2012 17:02 CET

Golden, Colorado—May 1, 2012—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, today responded to recent market activity concerning trading of VODG securities. The Company has become aware that an unaffiliated third party acting independently of the Company and without the prior knowledge of the Company released a promotional report regarding VODG on April 27, 2012 . While the Company cannot be certain, it is a reasonable inference that this report resulted in significant and unusual trading volume and

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Vitro Biopharma Responds to Recent Market Activity

Media